PCVX
Vaxcyte·NASDAQ
--
--(--)
--
--(--)
PCVX fundamentals
Vaxcyte (PCVX) released its earnings on Feb 24, 2026: revenue was 0 (YoY --), met estimates; EPS was -1.81 (YoY -77.45%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-1.81
-77.45%
Report date
Feb 24, 2026
PCVX Earnings Call Summary for Q4,2025
- Phase III Trials Initiated: OPUS-1, -2, -3 trials underway for VAX-31, targeting 6,000 adults to demonstrate noninferiority and broader serotype coverage.
- Manufacturing Readiness: $1B U.S. facility completed; commercial supply buildup underway for potential 2027 launch.
- Financial Strength: $2.4B cash post-equity offering; 2026 R&D expenses to rise for clinical and manufacturing scale-up.
- Group A Strep Resumption: Phase I safety study starting in adults, with potential for pediatric efficacy trials.
- Competitive Edge: 31-valent coverage vs. 20/21-valent competitors; focus on immune response superiority and serotype expansion.
Earnings
EPS
Revenue
Revenue & Expenses
Key Indicators
Vaxcyte (PCVX) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
Vaxcyte (PCVX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
Vaxcyte (PCVX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
Vaxcyte (PCVX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does Vaxcyte (PCVX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track Vaxcyte (PCVX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Vaxcyte’s earnings call?What is the revenue and EPS growth rate for Vaxcyte year over year?What factors drove the changes in Vaxcyte's revenue and profit?What is the market's earnings forecast for Vaxcyte next quarter?Did Vaxcyte beat or miss consensus estimates last quarter?What were the key takeaways from Vaxcyte's earnings call?What is Vaxcyte's latest dividend and current dividend yield?What guidance did Vaxcyte's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
